Recruiting
Edoxaban
Phase 4 Cardiovascular - AF
Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
Trial #: NCT06402851
Recruiting
Other/Multi
Other/Multi
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
Trial #: NCT06812117
Recruiting
I-DXd
Phase 1 Phase 2 Tumor-agnostic
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Trial #: NCT04145622
Recruiting
Quizartinib
Phase 1 Hematology
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Trial #: NCT06740799
Pages: 1  2  3  4  5  6  7  

The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.